A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML

被引：0
|
作者：
L M Kats
S J Vervoort
R Cole
A J Rogers
G P Gregory
E Vidacs
J Li
R Nagaraja
K E Yen
R W Johnstone
机构：
[1] Cancer Therapeutics Program,The Sir Peter MacCallum Department of Oncology
[2] Peter MacCallum Cancer Centre,undefined
[3] University of Melbourne,undefined
[4] Monash Haematology,undefined
[5] Monash Health and School of Clinical Sciences at Monash Health,undefined
[6] Monash University,undefined
[7] Bioinformatics Core,undefined
[8] Peter MacCallum Cancer Centre,undefined
[9] Agios Pharmaceuticals,undefined
来源：
Leukemia | 2017年 / 31卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1466 / 1470
页数：4
相关论文
共 28 条
  • [21] Functional characterization of combining epigenetic modifiers azacitidine and AG-221 in the TF-1:IDH2R140Q AML model
    Chopra, Vivek S.
    Avanzino, Brian
    Mavrommatis, Konstantinos
    Olshen, Adam
    DiMartino, Jorge
    MacBeth, Kyle J.
    CANCER RESEARCH, 2016, 76
  • [22] Enasidenib Monotherapy Is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 (m IDH2) Acute Myeloid Leukemia (AML)
    Pollyea, Daniel A.
    Tallman, Martin S.
    De Botton, Stephane
    DiNardo, Courtney D.
    Kantarjian, Hagop M.
    Collins, Robert H.
    Stein, Anthony S.
    Xu, Qiang
    Tosolini, Alessandra
    Gupta, Ira
    Agresta, Samuel V.
    Stein, Eytan M.
    BLOOD, 2017, 130
  • [23] AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model
    Quivoron, Cyril
    David, Muriel
    Straley, Kim
    Travins, Jeremy
    Kim, Hyeryun
    Chen, Yue
    Zhu, Dongwei
    Saada, Veronique
    Bawa, Olivia
    Opolon, Paule
    Polrot, Melanie
    Micol, Jean-Baptiste
    Willekens, Christophe
    Bernard, Olivier
    Yang, Hua
    Agresta, Sam
    de Botton, Stephane
    Yen, Katharine
    Penard-Lacronique, Virginie
    BLOOD, 2014, 124 (21)
  • [24] Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial
    Stein, Eytan M.
    Fathi, Amir T.
    Dinardo, Courtney D.
    Pollyea, Daniel A.
    Roboz, Gail J.
    Collins, Robert
    Sekeres, Mikkael A.
    Stone, Richard M.
    Attar, Eyal C.
    Frattini, Mark G.
    Tosolini, Alessandra
    Xu, Qiang
    See, Wendy L.
    MacBeth, Kyle J.
    de Botton, Stephane
    Tallman, Martin S.
    Kantarjian, Hagop M.
    LANCET HAEMATOLOGY, 2020, 7 (04): : E309 - E319
  • [25] Single Cell Characterisation of Transcriptional Programmes of Responsive and Resistant Leukaemic Progenitors in IDH2-Mutant Acute Myeloid Leukaemia in the AG221-AML-005 Study
    Chatzikyriakou, Prodromos
    Silveira, Douglas R. A.
    Alaez, Maria del Pilar Casares
    Usukhbayar, Batchimeg
    Metzner, Marlen
    Vyas, Paresh
    Gandhi, Anita K.
    Risueno, Alberto
    Hasan, Maroof
    Quek, Lynn
    BLOOD, 2022, 140 : 3414 - 3415
  • [26] A Multi-Center Open-Labeled Phase II Study of Intensive Salvage Therapy Followed By Enasidenib Maintenance for Patients with Relapsed/Refractory IDH2 mutant AML
    Thota, Swapna
    Bradley, Terrence J.
    Carraway, Hetty E.
    Griffiths, Elizabeth A.
    BLOOD, 2020, 136
  • [27] Phase III randomized, open-label study comparing the efficacy and safety of AG-221 vs conventional care regimens (CCR) in older patients with advanced acute myeloid leukemia (AML) with isocitrate dehydrogenase (IDH)-2 mutations in relapse or refractory to multiple prior treatments: the IDHENTIFY trial
    Tallman, Martin S.
    Knight, Robert D.
    Glasmacher, Axel G.
    Dohner, Hartmut
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
    DiNardo, Courtney D.
    Schuh, Andre C.
    Stein, Eytan M.
    Montesinos, Pau
    Wei, Andrew H.
    de Botton, Stephane
    Zeidan, Amer M.
    Fathi, Amir T.
    Kantarjian, Hagop M.
    Bennett, John M.
    Frattini, Mark G.
    Martin-Regueira, Patricia
    Lersch, Frederik
    Gong, Jing
    Hasan, Maroof
    Vyas, Paresh
    Doehner, Hartmut
    LANCET ONCOLOGY, 2021, 22 (11): : 1597 - 1608
123